{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:36:40Z","timestamp":1761709000784},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.dsx.2014.04.037","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T21:23:15Z","timestamp":1402953795000},"page":"145-151","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes"],"prefix":"10.1016","volume":"8","author":[{"given":"Souma\u00efla","family":"Camara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evariste","family":"Bouenizabila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel P.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie A.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel F.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2014.04.037_bib0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2014.04.037_bib0010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2014.04.037_bib0015","series-title":"Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications","first-page":"45","article-title":"Residual vascular risk in T2DM: the next frontier","author":"Hermans","year":"2011"},{"key":"10.1016\/j.dsx.2014.04.037_bib0020","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2014.04.037_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2014.04.037_bib0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-10-82","article-title":"Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus","volume":"10","author":"Nobels","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487312449414","article-title":"Optimal type 2 diabetes mellitus management: the randomized controlled OPTIMISE benchmarking study: baseline results from six European countries","volume":"20","author":"Hermans","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0045","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.2337\/dc12-1853","article-title":"for the OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) International Steering Committee. Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes: The OPTIMISE randomized, controlled trial","volume":"36","author":"Hermans","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2014.04.037_bib0050","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.dsx.2014.04.037_bib0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2014.04.037_bib0060","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2014.04.037_bib0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood\u2013glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2014.04.037_bib0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)","volume":"317","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Br Med J"},{"key":"10.1016\/j.dsx.2014.04.037_bib0075","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","article-title":"Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study","volume":"159","author":"Haffner","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0080","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dsx.2014.04.037_bib0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.dsx.2014.04.037_bib0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.dsx.2014.04.037_bib0095","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2014.04.037_bib0105","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0110","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0120","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2014.04.037_bib0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001786-199604000-00003","article-title":"Benchmarking: a data-oriented look at improving health care performance","volume":"10","author":"Czarnecki","year":"1996","journal-title":"J Nurs Care Qual"},{"key":"10.1016\/j.dsx.2014.04.037_bib0135","first-page":"77","article-title":"A new index of abdominal adiposity as an indicator of risk for cardiovascular disease. A cross-population study","volume":"17","author":"Valdez","year":"1993","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.dsx.2014.04.037_bib0140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2014.04.037_bib0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1475-2840-9-88","article-title":"Log(TG)\/HDL-C is related to both residual cardiometabolic risk and \u03b2-cell function loss in type 2 diabetes males","volume":"9","author":"Hermans","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1476-511X-11-132","article-title":"The atherogenic dyslipidemia ratio [log(TG)\/HDL-C] is associated with residual vascular risk. \u03b2-cell function loss and microangiopathy in type 2 diabetes females","volume":"11","author":"Hermans","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2014.04.037_bib0160","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s001250051215","article-title":"Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes","volume":"42","author":"Hermans","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2014.04.037_bib0165","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/diabetes.48.9.1779","article-title":"Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes","volume":"48","author":"Hermans","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2014.04.037_bib0170","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3132\/dvdr.2007.019","article-title":"Diabetic macro- and microvascular disease in type 2 diabetes","volume":"4","author":"Hermans","year":"2007","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.dsx.2014.04.037_bib0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsx.2008.02.004","article-title":"Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort","volume":"2","author":"Munoko","year":"2008","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2014.04.037_bib0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/diacare.27.1.201","article-title":"UKPDS 66 risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes","volume":"27","author":"Stevens","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2014.04.037_bib0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2362.2009.02234.x","article-title":"A catalogue of reporting guidelines for health research","volume":"40","author":"Simera","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.dsx.2014.04.037_bib0190","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999\u20132010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0195","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jacc.2013.01.044","article-title":"Risk factor control for coronary artery disease secondary prevention in large randomized trials","volume":"61","author":"Farkouh","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/07853890410033612","article-title":"Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes","volume":"36","author":"Gaede","year":"2004","journal-title":"Ann Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.18553\/jmcp.2006.12.4.303","article-title":"Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes","volume":"12","author":"Andros","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.dsx.2014.04.037_bib0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.dsx.2010.07.012","article-title":"The elusive type 2 diabetes individual at blood pressure control: a phenotypic characterization of goal-achieving patients","volume":"4","author":"Hermans","year":"2010","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2014.04.037_bib0215","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1185\/03007990903500565","article-title":"Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries","volume":"26","author":"Hermans","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dsx.2014.04.037_bib0220","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/2040622311413952","article-title":"Reducing vascular events risk in patients with dyslipidemia: an update for clinicians","volume":"2","author":"Hermans","year":"2011","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.dsx.2014.04.037_bib0225","first-page":"e13","article-title":"Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's Nfld","volume":"56","author":"McCrate","year":"2010","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.dsx.2014.04.037_bib0230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdiacomp.2012.03.014","article-title":"The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes","volume":"26","author":"Hermans","year":"2012","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.dsx.2014.04.037_bib0235","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2014.04.037_bib0240","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1440-1681.2008.05125.x","article-title":"Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes","volume":"36","author":"Owen","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.dsx.2014.04.037_bib0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12325-010-0034-5","article-title":"Engaging and empowering patients to manage their type 2 diabetes. Part 1: a knowledge, attitude, and practice gap?","volume":"27","author":"Serrano-Gil","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.dsx.2014.04.037_bib0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1751-7176.2010.00392.x","article-title":"Barriers to blood pressure control: a STITCH substudy","volume":"13","author":"Nelson","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402114000496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402114000496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:47:18Z","timestamp":1649422038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402114000496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1871402114000496"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2014.04.037","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2014.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Diabetes India. Published by Diabetes India All rights reserved.","name":"copyright","label":"Copyright"}]}}